GlassScriptPhysician profile
William P Davis
NPI 1407237365
$5,874.98
in general payments reported to CMS, 2019-2025
51 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,372 · 2020: $797 · 2021: $1,781 · 2022: $1,152 · 2023: $315 · 2024: $181 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $676.30 | 2019-2025 | |
| Abbvie INC. | $618.30 | 2021-2025 | Vraylar, Dalvance, Teflaro |
| Janssen Pharmaceuticals, INC | $403.62 | 2020-2022 | |
| Amgen INC. | $359.44 | 2019-2022 | |
| Lilly USA, LLC | $359.16 | 2019-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $283.45 | 2019-2022 | |
| Astellas Pharma US INC | $240.98 | 2019-2024 | Veozah |
| Esperion Therapeutics, INC. | $205.77 | 2021-2022 | |
| Novo Nordisk INC | $199.35 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $182.03 | 2021-2025 | Rexulti |
| Amarin Pharma, INC. | $163.93 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.15 | 2019-2021 | |
| Daiichi Sankyo INC. | $149.25 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $132.98 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $127.77 | 2019-2023 | Farxiga |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.